ATE233279T1 - Spezifisch bindende agentien - Google Patents

Spezifisch bindende agentien

Info

Publication number
ATE233279T1
ATE233279T1 AT91308147T AT91308147T ATE233279T1 AT E233279 T1 ATE233279 T1 AT E233279T1 AT 91308147 T AT91308147 T AT 91308147T AT 91308147 T AT91308147 T AT 91308147T AT E233279 T1 ATE233279 T1 AT E233279T1
Authority
AT
Austria
Prior art keywords
human antibody
reshaped
specific binding
binding agents
hmfg1
Prior art date
Application number
AT91308147T
Other languages
English (en)
Inventor
Martine Elisa Verhoeyen
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of ATE233279T1 publication Critical patent/ATE233279T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT91308147T 1990-09-07 1991-09-05 Spezifisch bindende agentien ATE233279T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909019553A GB9019553D0 (en) 1990-09-07 1990-09-07 Specific binding agents

Publications (1)

Publication Number Publication Date
ATE233279T1 true ATE233279T1 (de) 2003-03-15

Family

ID=10681827

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91308147T ATE233279T1 (de) 1990-09-07 1991-09-05 Spezifisch bindende agentien

Country Status (18)

Country Link
US (2) US6204366B1 (de)
EP (1) EP0483961B1 (de)
JP (2) JP3514456B2 (de)
KR (1) KR930702526A (de)
AT (1) ATE233279T1 (de)
AU (1) AU653167B2 (de)
BG (1) BG60716B1 (de)
CA (1) CA2090961C (de)
DE (1) DE69133200T2 (de)
DK (1) DK0483961T3 (de)
ES (1) ES2193129T3 (de)
FI (2) FI113873B (de)
GB (1) GB9019553D0 (de)
HU (2) HU9300609D0 (de)
NO (2) NO314595B1 (de)
RO (1) RO113432B1 (de)
UA (1) UA46691C2 (de)
WO (1) WO1992004380A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (de) 1991-06-14 2004-03-24 Genentech Inc. Verfahren zur Herstellung humanisierter Antikörper
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP0571613B1 (de) * 1991-12-13 2003-09-17 Xoma Corporation Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
WO1994011508A2 (en) * 1992-11-13 1994-05-26 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
US5792852A (en) * 1992-11-16 1998-08-11 Cancer Research Fund Of Contra Costa Polynucleotides encoding modified antibodies with human milk fat globule specificity
US6281335B1 (en) * 1993-10-08 2001-08-28 Coulter Corporation Hybridoma and anti-KC-4 humanized monoclonal antibody
AU6396494A (en) * 1992-11-16 1994-06-08 Cancer Research Fund Of Contra Costa Peptides and anti-sense peptides with broad neoplastic specificity
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
JPH07203974A (ja) * 1994-01-13 1995-08-08 Tosoh Corp 癌特異的ムチンを認識する抗体の遺伝子断片等
EP0781847A1 (de) * 1995-11-06 1997-07-02 MERCK PATENT GmbH Humanisierter monoklonaler Antikörper
IL136114A0 (en) * 1997-11-14 2001-05-20 Euro Celtique Sa Immunoglobulin molecules having a synthetic variable region and modified specificity
GB2360771A (en) * 2000-03-28 2001-10-03 Antisoma Res Ltd Compounds for targeting
WO2001074905A1 (en) * 2000-04-03 2001-10-11 Antisoma Research Limited Compounds for targeting
AU2002307064A1 (en) * 2001-04-02 2002-10-15 Purdue Pharma L.P. Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response
GB0200657D0 (en) * 2002-01-12 2002-02-27 Antisoma Plc Cancer treatment
CA2488441C (en) * 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
AU2003256566A1 (en) * 2002-07-16 2004-02-02 Stuart Bussell Methods to construct multimeric dna and polymeric protein sequences as direct fusions or with linkers
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
EP1973951A2 (de) * 2005-12-02 2008-10-01 Genentech, Inc. Bindende polypeptide mit eingeschränkten diversitätssequenzen
KR101920250B1 (ko) 2010-10-13 2018-11-20 얀센 바이오테크 인코포레이티드 인간 온코스타틴 m 항체 및 이용 방법
US20140079722A1 (en) * 2011-03-09 2014-03-20 Centrose, Llc Extracellular targeted drug conjugates
RU2493165C1 (ru) * 2012-02-28 2013-09-20 Общество с ограниченной ответственностью "Технофарма" Наноантитело, специфически связывающее белок muc1, способ детекции белка muc1 с помощью наноантител
EP3363462A1 (de) 2012-04-30 2018-08-22 Biothera, Inc. Zusammensetzungen und verfahren für beta-glucan-immuntherapie

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
CA1339204C (en) * 1987-01-07 1997-08-05 Joyce Taylor-Papadimitriou Mucin core polypeptide, antibodies and probes
ATE243754T1 (de) * 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
AU3049189A (en) * 1988-02-08 1989-08-25 John Muir Cancer & Aging Institute Monoclonal antibody specific to a novel mucin-like glycoprotein surface antigen on human carcinoma cells
EP0442926A1 (de) * 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptide
CA2003211A1 (en) * 1988-11-17 1990-05-17 Pei-Xiang Xing Monoclonal antibodies
US5075219A (en) * 1989-04-05 1991-12-24 John Muir Cancer & Aging Institute Monoclonal antibody which recognizes a specific glycoprotein of a human milk-fat globule membrane mucin antigen and said mucin antigen
ES2075169T3 (es) * 1989-11-17 1995-10-01 Unilever Nv Agentes de union especifica.

Also Published As

Publication number Publication date
ES2193129T3 (es) 2003-11-01
NO930825L (no) 1993-05-05
NO315239B1 (no) 2003-08-04
HU9300609D0 (en) 1993-05-28
JPH06500468A (ja) 1994-01-20
WO1992004380A1 (en) 1992-03-19
HUT67796A (en) 1995-04-28
US6204366B1 (en) 2001-03-20
NO20014822D0 (no) 2001-10-04
NO930825D0 (no) 1993-03-05
CA2090961C (en) 2004-01-20
GB9019553D0 (en) 1990-10-24
DE69133200T2 (de) 2003-11-20
AU8495391A (en) 1992-03-30
FI930984A0 (fi) 1993-03-05
AU653167B2 (en) 1994-09-22
FI930984L (fi) 1993-03-05
DK0483961T3 (da) 2003-06-23
BG97607A (bg) 1994-03-31
NO314595B1 (no) 2003-04-14
US20020086978A1 (en) 2002-07-04
FI114611B (fi) 2004-11-30
JP3514456B2 (ja) 2004-03-31
EP0483961A1 (de) 1992-05-06
KR930702526A (ko) 1993-09-09
UA46691C2 (uk) 2002-06-17
DE69133200D1 (de) 2003-04-03
FI113873B (fi) 2004-06-30
RO113432B1 (ro) 1998-07-30
CA2090961A1 (en) 1992-03-08
EP0483961B1 (de) 2003-02-26
BG60716B1 (en) 1996-01-31
NO20014822L (no) 1993-05-05
JP2003061689A (ja) 2003-03-04

Similar Documents

Publication Publication Date Title
ATE233279T1 (de) Spezifisch bindende agentien
PT99934A (pt) Processo para a producao de um anticorpo anti-htnf alfa recombinante ou humanizado
FI840219A0 (fi) Human-humanhybridom foer neoplasmer
BR9708910A (pt) Anticorpo conjugado sequência de polinucleotídeos vetor célula hospedeira hibridoma composição farmacêutica processos para fabricar um anticorpo ou um conjugado e para tratar um humano ou animal em necessidade deste tratamento
PE20020972A1 (es) Anticuerpos recombinantes asociados a gangliosidos
DK0429242T3 (da) Specifikke bindingsmidler
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
DK0687295T3 (da) Human B-lymfoblastoidcellelinje, der secernerer anti-gangliosid-antistof
BG99074A (bg) Рекомбинантни човешки нiv-неутрализиращи моноклонални антитела за профилактика и лечение на нiv инфекция
NO174110C (no) Monoklonalt antistoff til anvendelse in vitro for diagnose av maligne tumor- eller akutte inflammasjonssykdommer, og som er spesifikt for N-acetyl-neuraminsyre i hybridom som produserer antistoffet
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
RU93033872A (ru) Связывающие агенты, антитела, клетки плазмиды, применение плазмид, днк, вариабельные области антител, композиция, применение связующих агентов
FR2697088B1 (fr) Anticorps monoclonaux pour le diagnostic différentiel de cancers épithéliaux dans des épanchements séreux, hybridomes les secrétant et kit de diagnostic.
ATE84069T1 (de) Murin-hybridoma lym-2 und diagnostikantikoerper, der dadurch hergestellt ist.
DK1414859T5 (da) Monoklonale anti-SSRP-1-antistoffer og hybridomer som producerer antistofferne
DE3787220D1 (de) Monoklonaler Antikörper gegen menschliches Plasminogen, Verfahren zu seiner Herstellung, diesen Antikörper enthaltendes Testreagenz sowie Testsatz und diesen Antikörper produzierendes Hybridoma.
RU93058456A (ru) Антитела, способы диагностики, способ лечения, фармацевтическая композиция, клеточные линии
DK182188A (da) Humant tumorassocieret antigen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0483961

Country of ref document: EP

EELA Cancelled due to lapse of time